Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sleep study

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,052 result(s) found for: Sleep study. Displaying page 2 of 53.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2023-000062-34 Sponsor Protocol Number: Reb-Oxy-OSA Start Date*: 2023-06-02
    Sponsor Name:CHU Brugmann
    Full Title: Combination of Reboxetine 4mg and Oxybutynin 5mg for treating moderate obstructive sleep apnea: a one-month randomized placebo-controlled double-blind study
    Medical condition: Obstructive sleep apnea
    Disease: Version SOC Term Classification Code Term Level
    25.0 100000004855 10055577 Obstructive sleep apnea syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003037-41 Sponsor Protocol Number: MUG-EROS-2012 Start Date*: 2012-09-21
    Sponsor Name:Medizinische Universität Graz, Universitätsklinik für Innere Medizin, Klinische Abteilung für Lungenkrankheiten
    Full Title: Effects of Roflumilast on pulmonary vascular resistance in patients with COPD and sleep apnea (Overlap Syndrome) with and without non-invasive ventilation. A Pilot Study.
    Medical condition: This study is about pulmonary hypertension due to lung diseases. The lung disease in this study will be the overlap syndrome which is defined as chronic obstructive pulmonary disease concomitant wi...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10040976 Sleep apnea syndrome LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-004520-35 Sponsor Protocol Number: VP-VEC-162-3204 Start Date*: 2012-12-06
    Sponsor Name:Vanda Pharmaceuticals Inc.
    Full Title: AN EXTENSION OPEN-LABEL SAFETY STUDY OF A 24-MONTH 20MG DOSE REGIMEN OF TASIMELTEON FOR THE TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER (N24HSWD) IN BLIND INDIVIDUALS WITH NO LIGHT PERCEPTION WHO ...
    Medical condition: Blind males or females with no conscious light perception and the complaint of a sleep-wake disorder associated with Non-24 Hour Sleep- Wake Disorder
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029205 - Nervous system disorders 10009191 Circadian rhythm sleep disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-015859-24 Sponsor Protocol Number: Zon-001 Start Date*: 2010-02-24
    Sponsor Name:The Sahlgrenska Academy, University of Gothenburg
    Full Title:
    Medical condition: The objective is to explore the efficacy of pharmacological weight reduction compared with CPAP treatment in patients with moderate to severe obstructive sleep apnea (OSA).
    Disease: Version SOC Term Classification Code Term Level
    12.0 10055577 Obstructive sleep apnea syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-004866-33 Sponsor Protocol Number: CA-BP13 Start Date*: 2014-04-04
    Sponsor Name:Göteborgs Universitet
    Full Title: A short term open, randomized cross over trial trial exploring the effect of carbonic anhydrase inhibition by acetazolamide on sleep apnea associated hypertension
    Medical condition: obstructive sleep apnea related hypertension
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10055577 Obstructive sleep apnea syndrome LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-003939-32 Sponsor Protocol Number: APL-510-008 Start Date*: 2005-03-23
    Sponsor Name:Alliance Pharmaceuticals Ltd
    Full Title: A double-blind placebo controlled cross-over study to determine if 1.5 and 3mg of APL510 can normalise sleep patterns in elderly subjects with difficulty in maintenance of sleep and/or initiating s...
    Medical condition: Difficulty in maintenance of sleep and/or initiating sleep onset
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003822-28 Sponsor Protocol Number: EFC10480 Start Date*: 2008-03-05
    Sponsor Name:sanofi-aventis recherche et développement
    Full Title: Comparison of the safety and efficacy of eplivanserin and lormetazepam in the treatment of insomnia characterized by sleep maintenance difficulties. A 4 week, randomized, double-blind, comparative,...
    Medical condition: Chronic primary insomnia and sleep maintenance difficulties.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) PT (Completed) FR (Completed) ES (Completed) EE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2011-005792-16 Sponsor Protocol Number: Rocuronium_HVR_OSAS Start Date*: 2012-02-10
    Sponsor Name:Karolinska University Hospital
    Full Title: Effect of reduced cholinergic transmission by rocuronium on the hypoxic ventilatory response in patients with obstructive sleep apnea - before and after three months of continous positive airway pr...
    Medical condition: Obstuctive sleep apnea and acute hypoxic ventilatory response
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10055577 Obstructive sleep apnea syndrome LLT
    Population Age: Adults Gender: Male
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000220-18 Sponsor Protocol Number: C.2524.0472.01 Start Date*: 2013-03-25
    Sponsor Name:University of Amsterdam
    Full Title: Effects of melatonin treatment, light therapy, and sleep improvement on psychosocial, cognitive, and behavioural outcomes in children with Delayed Sleep Phase Syndrome and their parents
    Medical condition: Delayed Sleep Phase Syndrome
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000281-35 Sponsor Protocol Number: VP-VEC-162-3201 Start Date*: 2011-06-09
    Sponsor Name:Vanda Pharmaceuticals Inc.
    Full Title: A Multicenter, Randomized, Double-Mask, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of 20 mg Tasimelteon versus Placebo in Totally Blind Subjects with N24HSWD followed...
    Medical condition: Blind males or females with no conscious light perception and the complaint of a sleep-wake disorder associated with Non-24 Hour Sleep-Wake Disorder.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10009191 Circadian rhythm sleep disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-003791-22 Sponsor Protocol Number: EFC10844 Start Date*: 2009-01-19
    Sponsor Name:sanofi-aventis Recherche & Développement
    Full Title: Efficacy and safety of eplivanserin 5mg/day in insomnia characterized by sleep maintenance difficulties: a 6-week, randomized, double-blind, placebo-controlled, polysomnography study
    Medical condition: insomnia characterized by sleep maintenance difficulties
    Disease: Version SOC Term Classification Code Term Level
    11.0 10027590 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) DE (Completed) AT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-000645-23 Sponsor Protocol Number: Borealis1 Start Date*: 2015-06-19
    Sponsor Name:CIBER (Centro de Investigacion Biomedica en Red)
    Full Title: Safety, tolerability and efficacy of nocturnal hypertension treatment with domperidone in the sleep apnea-hypopnea syndrome. Pilot study.
    Medical condition: Nocturnal hypertension in the sleep apnea-hypopnea syndrome.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004855 10040976 Sleep apnea syndrome LLT
    17.1 100000004866 10019180 HBP LLT
    Population Age: Adults Gender: Male
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004620-10 Sponsor Protocol Number: 719-13 Start Date*: 2014-12-22
    Sponsor Name:Johan Hellgren
    Full Title: A double blind, placebo controlled randomized study of nasal steroid spray treatment on the quality of life and objective sleep parameters in children with sleep disorder breathing.
    Medical condition: Sleep disordered breathing due to enlarged tonsils and/or adenoid
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003460-31 Sponsor Protocol Number: COP13.058 Start Date*: 2014-03-03
    Sponsor Name:GGZ-Drenthe
    Full Title: The effect of low doses of mirtazapine and quetiapine on sleep and daytime functioning.
    Medical condition: Insomnia
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003394-15 Sponsor Protocol Number: VP-VEC-162-4201 Start Date*: 2016-06-28
    Sponsor Name:Vanda Pharmaceuitcals Inc.
    Full Title: OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS AND SAFETY OF TASIMELTEON IN TOTALLY BLIND CHILDREN AND ADOLESCENTS WITH NON-24-HOUR SLEEP- WAKE DISORDER
    Medical condition: This study will be an open-label, single dose, non-controlled trial to evaluate the pharmacokinetics and safety of tasimelteon in children who are 3 years to less than 18 years of age, totally blin...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10040984 Sleep disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-004552-41 Sponsor Protocol Number: I8F-MC-GPI2 Start Date*: 2022-09-14
    Sponsor Name:Eli Lilly and Company
    Full Title: A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants who have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Tria...
    Medical condition: Obstructive sleep apnea
    Disease: Version SOC Term Classification Code Term Level
    25.0 10038738 - Respiratory, thoracic and mediastinal disorders 10029983 Obstructive sleep apnoea syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2020-000520-19 Sponsor Protocol Number: BAY2586116/20849 Start Date*: 2021-02-10
    Sponsor Name:Bayer AG
    Full Title: Proof-of-concept, multi-center, randomized, double-blind, placebo-controlled, two-way crossover study to investigate the effect strength of BAY 2586116 on the apnea-hypopnea-index after repetitive ...
    Medical condition: Sleep Apnea, Obstructive
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10055577 Obstructive sleep apnea syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003766-27 Sponsor Protocol Number: 848015011 Start Date*: 2018-07-18
    Sponsor Name:VU University Medical Centre
    Full Title: The DREAMING study: Efficacy of low dose amitriptyline and mirtazapine for insomnia disorder: a double-blind, randomized, placebo-controlled trial in general practice
    Medical condition: Insonnia disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10078083 Insomnia disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-001492-30 Sponsor Protocol Number: EFC10550 Start Date*: 2008-08-25
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: Comparison of the safety and efficacy of volinanserin and lormetazepam in the treatment of insomnia characterized by sleep maintenance difficulties. A 4 week, randomized, double-blind, double-dummy...
    Medical condition: Insomnia characterized by sleep maintenance difficulties
    Disease: Version SOC Term Classification Code Term Level
    11.0 10027590 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Completed) FR (Completed) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002116-32 Sponsor Protocol Number: MTM-04 Start Date*: 2015-09-23
    Sponsor Name:Køge Hospital
    Full Title: The effect of MElatonin on Depression, Anxiety, CIrcadian and Sleep disturbances in patients after acute myocardial syndrome
    Medical condition: Depression Anxiety Sleep disturbances Circadian disturbances
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10009190 Circadian dysrhythmia LLT
    19.0 100000004873 10002865 Anxiety reaction LLT
    19.0 100000004873 10040999 Sleep disturbed LLT
    19.0 100000004873 10012402 Depressive episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 22 08:18:50 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA